Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.62 USD
-0.04 (-2.41%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.63 +0.01 (0.62%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATNM 1.62 -0.04(-2.41%)
Will ATNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Other News for ATNM
Actinium Pharmaceuticals (ATNM) Showcases Promising Prostate Cancer Treatment Data
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer ...
Actinium Pharmaceuticals' ATNM-400 shows improved survival in prostate cancer
Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals
Actinium Pharma (ATNM) Rating Reaffirmed with Stable Price Target | ATNM Stock News